check_circleStudy Completed

Pregnancy

Bayer Identifier:

17714

ClinicalTrials.gov Identifier:

NCT02414919

EudraCT Number:

Not Available

EU CT Number:

Not Available
Duration of use of highly effective reversible contraception

Trial purpose

To assess the proportion of women who use HERC for ≥2 years of duration

Key Participants Requirements

Sex

Female

Age

15 - 44 Years
  • -Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012

Trial summary

Enrollment Goal
13880
Trial Dates
April 2015 - March 2016
Phase
N/A
Could I Receive a placebo
No
Products
Mirena (Levonorgestrel IUS, BAY86-5028)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Salt Lake, United States

Primary Outcome

  • Proportion of women who use HERC
    date_rangeTime Frame:
    2 years post-HERC initiation
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Duration of real world use of three different HERC devices
    date_rangeTime Frame:
    2 years post-HERC initiation

Trial design

Real-world duration of use for highly effective reversible contraception (HERC): A retrospective review
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.